MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review

Mirum and Incyte said zilurgisertib cut new bone lesion formation in fibrodysplasia ossificans progressiva (FOP), while the FDA has begun Priority Review of the NDA with a decision date set for Sept. 26, 2026. The update improves the drug's regulatory trajectory and supports the case for approval in this rare-disease program. The news is constructive for both companies, though the market impact is likely limited to the shares directly involved.

Analysis

Mirum and Incyte said zilurgisertib cut new bone lesion formation in fibrodysplasia ossificans progressiva (FOP), while the FDA has begun Priority Review of the NDA with a decision date set for Sept. 26, 2026. The update improves the drug's regulatory trajectory and supports the case for approval in this rare-disease program. The news is constructive for both companies, though the market impact is likely limited to the shares directly involved.